v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule Of Revenue Sources Health Care Organization Table Text Block
Net service revenue by payor class as a percentage of total net service revenue for each of our operating segments, which are described in Note 8 - Segment Information, is as follows:
For the Three-Month Periods Ended June 30,For the Six-Month Periods
Ended June 30,
2025202420252024
Home Health:
     Medicare35 %36 %35 %37 %
     Non-Medicare - Episodic-based9 %8 %9 %8 %
     Non-Medicare - Non-episodic based20 %19 %20 %19 %
Hospice:
     Medicare33 %33 %33 %33 %
     Non-Medicare1 %2 %1 %2 %
High Acuity Care2 %2 %2 %1 %
100 %100 %100 %100 %
Schedule of Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):
 Fair Value at Reporting Date Using
Financial InstrumentCarrying Value as of June 30, 2025Quoted Prices in Active
Markets for Identical
Items
(Level 1)		Significant Other
Observable Inputs
(Level 2)		Significant
Unobservable Inputs
(Level 3)
$450.0 million Term Loan$338.1 $— $333.9 $— 
Schedule of Weighted-Average Shares Outstanding The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):
 For the Three-
Month Periods
Ended June 30,		For the Six-
Month Periods
Ended June 30,
 2025202420252024
Weighted average number of shares outstanding - basic32,849 32,706 32,822 32,688 
Effect of dilutive securities:
Stock options11 10 10 10 
Non-vested stock and stock units429 331 399 294 
Weighted average number of shares outstanding - diluted33,289 33,047 33,231 32,992 
Anti-dilutive securities177 224 409 472